Case Reports in Hematology / 2020 / Article / Fig 2

Case Report

Treatment of T-Cell Prolymphocytic Leukemia with Central Nervous System Involvement Using Intrathecal Alemtuzumab Administration

Figure 2

Treatment time course for the leukemia and central nervous system involvement. ALM: alemtuzumab; CSF: cerebrospinal fluid; FC: fludarabine and cyclophosphamide; HSCT: hematopoietic stem-cell transplantation; IT: intrathecal treatment; IV: intravenous treatment; MTX: methotrexate; WBI: whole brain irradiation; and WSI: whole spine irradiation. Triplets consist of 15 mg of methotrexate, 40 mg of cytarabine, and 20 mg of prednisolone.

We are experiencing issues with article search and journal table of contents. We are working on a fix as to remediate it and apologise for the inconvenience.

Article of the Year Award: Outstanding research contributions of 2020, as selected by our Chief Editors. Read the winning articles.